Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 88 (8), 1256-62

BRCA1 and BRCA2 Mutations in Scotland and Northern Ireland

BRCA1 and BRCA2 Mutations in Scotland and Northern Ireland

Scottish/Northern Irish BRCAI/BRCA2 Consortium. Br J Cancer.


BRCA1 and BRCA2 mutations have been identified in 107 families in Scotland and Northern Ireland. Ninety-seven of these families had been referred to regional cancer genetics centres and a further 10 were identified from a sequential series of male breast cancers treated in Edinburgh. Fifty-nine of the families had a mutation in BRCA1 and 46 in BRCA2. Two families had both. Family trees were extended and cancer diagnoses verified by means of the unusually complete and accessible Scottish and Northern Irish records. Ten specific recurring mutations (five in each gene) accounted for almost half of the total detected, and almost one-quarter were accounted for by just two (BRCA1 2800 delAA and BRCA2 6503 delTT). The prevalence of breast cancer is similar for BRCA1 and BRCA2 mutation families (average 3.7 and 3.6 per family), but the former have a much greater risk of ovarian cancer (average 1.5 and 0.6 per family, respectively). For breast cancer, age of onset tended to be younger in BRCA1 mutation carriers but, for ovarian cancer, there was no difference between BRCA1 and BRCA2 families in mean age at diagnosis. Mutations within the 5' two-thirds of BRCA1 carry a significantly higher relative risk of ovarian cancer and the same is true for mutations within the central portion of BRCA2 (the 'OCCR'). In the former case, this appears to be because of differences in absolute risk for both ovarian and breast cancer, while, in the latter, only ovarian cancer risk varies significantly. The findings confirm that founder mutations are present within the Scottish/Northern Irish population and have implications for the organisation of molecular screening services.


Figure 1
Figure 1
Diagrammatic representation of BRCA1 exons (plus intronic regions with pathogenic mutations, shown shaded). Vertical lines above the diagram represent all mutations detected, with heights proportional to numbers of cases. Actual numbers are given for most frequent mutations. Circles below the diagram represent families with at least three breast or ovarian cancers attributed to each mutation. The darker segment of each circle represents the proportion of breast cancers and the paler segment the proportion of ovarian cancers.
Figure 2
Figure 2
Diagram of BRCA2 exons, with the position of the ‘OCCR’ indicated. Annotation and symbols are as for Figure 1.

Similar articles

See all similar articles

Cited by 11 PubMed Central articles

See all "Cited by" articles


    1. Bodmer JG, Kennedy LJ, Lindsay J, Wasik AM. Applications of serology and the ethnic distribution of three locus HLA haplotypes. Br Med Bull. 1987;43:94–121. - PubMed
    1. Cippolini G, Ghimenti C, Sensi E, Iandolo A, Piccirilli A, Berti A, Naccarato G, Viacava P, Campani D, Bevilaqua G, Caligo MA. Mutation analysis of BRCA1 and BRCA2 in Italian hereditary and sporadic forms of breast and ovarian cancers: tumor genotype–phenotype correlation in breast cancer BRCA-mutation carriers. Dis Markers. 1999;15:101–102.
    1. Claes K, Machackova E, DeVos M, Poppe B, DePaepe A, Messiaen L. Mutation analysis of the BRCA1 and BRCA2 genes in the Belgian patient population and identification of a Belgian founder mutation. Dis markers. 1999;15:69–73. - PMC - PubMed
    1. Collyer S, DeMay R. Public records and recognition of genetic disease in Scotland. Clin Genet. 1987;31:125–131. - PubMed
    1. Couch FJ, DeShano ML, Blackwood MA. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med. 1997;336:1409–1415. - PubMed

Publication types